The Pharmacology of Reversible Monoamine Oxidase Inhibitors
- 1 October 1989
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 155 (S6) , 66-71
- https://doi.org/10.1192/s0007125000297511
Abstract
The older monoamine oxidase inhibitors (MAOIs) are mechanism-based, irreversible inhibitors of MAO; most inhibit both the A and B forms of MAO. Several of the drugs are hydrazine derivatives which have non-specific effects other than MAO inhibition. These properties convey disadvantages, which may be seen as serious, though infrequent, adverse events — the ‘cheese effect’, hepatotoxicity, amphetamine-like activity, orthostatic hypotension and anticholinergic effects. New, reversible MAOIs stem from a variety of chemical classes and are more specific in their effects, with relatively rapid onset of action, direct relationship between plasma concentration and pharmacological effect, and no prolonged carry-over phenomena.Keywords
This publication has 21 references indexed in Scilit:
- Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.British Journal of Clinical Pharmacology, 1989
- Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamineBiochemistry, 1985
- SUICIDE SUBSTRATES, MECHANISM-BASED ENZYME INACTIVATORS: RECENT DEVELOPMENTSAnnual Review of Biochemistry, 1984
- Monoamine oxidase inhibition by tranylcypromine: Assessment in human volunteersEuropean Journal of Clinical Pharmacology, 1982
- Cumulative effects of irreversible MAO inhibitors in vivoBiochemical Pharmacology, 1979
- Substrate-selective monoamine oxidases—inhibitor, tissue, species and functional differencesBiochemical Pharmacology, 1978
- Suicide enzyme inactivatorsAccounts of Chemical Research, 1976
- Atypical Facial Pain and DepressionThe British Journal of Psychiatry, 1966